NT-proBNP levels significantly decreased in the overall population and in patients without T2DM, but not in those with T2DM, suggesting that the cardioprotective effects of esaxerenone may be limited in patients with T2DM. This evidence concerns the gene NPPB and type 2 diabetes mellitus.